NewLink Genetics Corp (NASDAQ:NLNK) shares traded up 1.1% on Wednesday . The company traded as high as $4.64 and last traded at $4.62. 551,113 shares changed hands during mid-day trading, a decline of 51% from the average session volume of 1,121,691 shares. The stock had previously closed at $4.57.
A number of research analysts have recently weighed in on the company. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics and gave the company a “buy” rating in a research note on Monday, January 8th. Bank of America decreased their price objective on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, March 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $21.00 price objective (down previously from $25.00) on shares of NewLink Genetics in a research note on Friday, March 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $12.86.
The company has a market cap of $169.80, a P/E ratio of -1.96 and a beta of 1.22.
NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.32. The business had revenue of $10.10 million for the quarter, compared to analyst estimates of $2.72 million. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. equities research analysts expect that NewLink Genetics Corp will post -2.32 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its stake in NewLink Genetics by 1.2% in the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after buying an additional 4,630 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in NewLink Genetics by 3.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in NewLink Genetics by 207.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock worth $3,176,000 after buying an additional 210,360 shares during the last quarter. Stifel Financial Corp acquired a new stake in NewLink Genetics in the 3rd quarter worth about $402,000. Finally, Point72 Asset Management L.P. acquired a new stake in NewLink Genetics in the 3rd quarter worth about $1,819,000. 65.05% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “NewLink Genetics (NLNK) Trading 1.1% Higher” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/20/newlink-genetics-nlnk-trading-1-1-higher.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.